Intensity Therapeutics
INTS
20 hedge funds and large institutions have $4.79M invested in Intensity Therapeutics in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0.21% more ownership
Funds ownership: 0.51% → 0.72% (+0.21%)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
28% less capital invested
Capital invested by funds: $6.65M → $4.79M (-$1.86M)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.27M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$43.5K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$20.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.28K |
| 5 |
BlackRock
New York
|
+$363 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sapient Capital
Indianapolis,
Indiana
|
-$197K |
| 2 |
SL
Sentinus LLC
Oak Brook,
Illinois
|
-$72.3K |
| 3 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
-$70.2K |
| 4 |
GS
GTS Securities
Miami,
Florida
|
-$53.1K |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$52.3K |
INTS Hedge Fund Activity: Q4 2024 in Review
20 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q4 2024, worth a combined $4.79M — down 28% from $6.65M a quarter earlier.
Fund positioning in INTS was balanced in Q4 2024: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.27M. The largest seller was Sapient Capital, cutting an estimated $197K.
- 20 institutional investors held Intensity Therapeutics (INTS) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $4.79M of Intensity Therapeutics stock for Q4 2024, down 28% quarter-over-quarter.
- 3 funds opened new Intensity Therapeutics positions in Q4 2024 and 3 closed out, a net change of 0 holders.
- The largest Intensity Therapeutics buyer in Q4 2024 was Armistice Capital, an estimated $3.27M added.
- The largest Intensity Therapeutics seller in Q4 2024 was Sapient Capital, an estimated $197K sold.
Based on aggregated 13F filings for Q4 2024.